Cargando…
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting
Patients with severe OCS-dependent asthma can be considered a subgroup of asthma patients with severe disease and great risk of complications, related to chronic OCS use. The introduction of biological drugs has represented a turning point in the therapeutic strategy for severe asthma, offering a va...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918073/ https://www.ncbi.nlm.nih.gov/pubmed/36769635 http://dx.doi.org/10.3390/jcm12030985 |
_version_ | 1784886522119454720 |
---|---|
author | Vitale, Carolina Maglio, Angelantonio Pelaia, Corrado D’Amato, Maria Ciampo, Luigi Pelaia, Giulia Molino, Antonio Vatrella, Alessandro |
author_facet | Vitale, Carolina Maglio, Angelantonio Pelaia, Corrado D’Amato, Maria Ciampo, Luigi Pelaia, Giulia Molino, Antonio Vatrella, Alessandro |
author_sort | Vitale, Carolina |
collection | PubMed |
description | Patients with severe OCS-dependent asthma can be considered a subgroup of asthma patients with severe disease and great risk of complications, related to chronic OCS use. The introduction of biological drugs has represented a turning point in the therapeutic strategy for severe asthma, offering a valid alternative to OCS. Benralizumab, like other anti-IL-5 agents, has been shown to reduce exacerbations and OCS intake/dosage and improve symptom control and lung function. While these findings have also been confirmed in real-life studies, data on long-term efficacy are still limited. Methods: In this retrospective study, we evaluated the effects of 2 years of treatment with benralizumab on 44 patients with OCS-dependent severe asthma by analyzing clinical, biological and functional data. Results: After 2 years of benralizumab, 59.4% discontinued OCS and patients who continued to use OCS had their mean dose reduced by approximately 85% from baseline. Meanwhile, 85% of patients had their asthma well-controlled (ACT score > 20) and had no exacerbations, and 41.6% had normal lung function. Conclusions: Our findings support the long-term effectiveness of benralizumab in severe OCS-dependent asthma in a real-life setting, suggesting potential reductive effects on costs and complications such as adverse pharmacological events. |
format | Online Article Text |
id | pubmed-9918073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99180732023-02-11 Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting Vitale, Carolina Maglio, Angelantonio Pelaia, Corrado D’Amato, Maria Ciampo, Luigi Pelaia, Giulia Molino, Antonio Vatrella, Alessandro J Clin Med Article Patients with severe OCS-dependent asthma can be considered a subgroup of asthma patients with severe disease and great risk of complications, related to chronic OCS use. The introduction of biological drugs has represented a turning point in the therapeutic strategy for severe asthma, offering a valid alternative to OCS. Benralizumab, like other anti-IL-5 agents, has been shown to reduce exacerbations and OCS intake/dosage and improve symptom control and lung function. While these findings have also been confirmed in real-life studies, data on long-term efficacy are still limited. Methods: In this retrospective study, we evaluated the effects of 2 years of treatment with benralizumab on 44 patients with OCS-dependent severe asthma by analyzing clinical, biological and functional data. Results: After 2 years of benralizumab, 59.4% discontinued OCS and patients who continued to use OCS had their mean dose reduced by approximately 85% from baseline. Meanwhile, 85% of patients had their asthma well-controlled (ACT score > 20) and had no exacerbations, and 41.6% had normal lung function. Conclusions: Our findings support the long-term effectiveness of benralizumab in severe OCS-dependent asthma in a real-life setting, suggesting potential reductive effects on costs and complications such as adverse pharmacological events. MDPI 2023-01-27 /pmc/articles/PMC9918073/ /pubmed/36769635 http://dx.doi.org/10.3390/jcm12030985 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vitale, Carolina Maglio, Angelantonio Pelaia, Corrado D’Amato, Maria Ciampo, Luigi Pelaia, Giulia Molino, Antonio Vatrella, Alessandro Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting |
title | Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting |
title_full | Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting |
title_fullStr | Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting |
title_full_unstemmed | Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting |
title_short | Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting |
title_sort | effectiveness of benralizumab in ocs-dependent severe asthma: the impact of 2 years of therapy in a real-life setting |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918073/ https://www.ncbi.nlm.nih.gov/pubmed/36769635 http://dx.doi.org/10.3390/jcm12030985 |
work_keys_str_mv | AT vitalecarolina effectivenessofbenralizumabinocsdependentsevereasthmatheimpactof2yearsoftherapyinareallifesetting AT maglioangelantonio effectivenessofbenralizumabinocsdependentsevereasthmatheimpactof2yearsoftherapyinareallifesetting AT pelaiacorrado effectivenessofbenralizumabinocsdependentsevereasthmatheimpactof2yearsoftherapyinareallifesetting AT damatomaria effectivenessofbenralizumabinocsdependentsevereasthmatheimpactof2yearsoftherapyinareallifesetting AT ciampoluigi effectivenessofbenralizumabinocsdependentsevereasthmatheimpactof2yearsoftherapyinareallifesetting AT pelaiagiulia effectivenessofbenralizumabinocsdependentsevereasthmatheimpactof2yearsoftherapyinareallifesetting AT molinoantonio effectivenessofbenralizumabinocsdependentsevereasthmatheimpactof2yearsoftherapyinareallifesetting AT vatrellaalessandro effectivenessofbenralizumabinocsdependentsevereasthmatheimpactof2yearsoftherapyinareallifesetting |